| Field | Specification |
|---|---|
| Mfr No | |
| Accession Number | |
| Alternative Names | Gamma-aminobutyric acid receptor subunit alpha-5, GABA(A) receptor subunit alpha-5, GABRA5, Gamma aminobutyric acid A receptor alpha 5, GBRA5_HUMAN |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | Fusion protein amino acids 368-419 (last cytoplasmic domain before extracellular C-terminus) of human GABA A Receptor Alpha5. |
| Isotype | |
| Product Type | |
| Reactivity | |
| Shipping | |
| Storage | |
| Target |
The GABA-A receptor alpha 5 subunit (GABRA5) is a critical component of the GABA-A receptor complex, the brain’s primary fast-acting inhibitory neurotransmitter system. As part of the ligand-gated ion channel superfamily, GABRA5 is predominantly expressed in the hippocampus, where it plays a central role in modulating tonic inhibition, synaptic plasticity, and cognitive function.
Recent research has highlighted GABRA5 as a promising target in neurodegenerative disease, particularly Alzheimer’s disease. Inverse agonists selective for GABRA5-containing receptors have shown potential in enhancing learning and memory by reducing excessive inhibitory tone, which is often elevated in neurodegenerative states. This modulation of GABRA5 activity may help restore excitatory-inhibitory balance, improve cognitive performance, and slow disease progression.
Beyond Alzheimer’s, GABRA5 is also being investigated for its role in age-related cognitive decline and other neurological disorders characterized by impaired GABAergic signaling. Its unique pharmacological profile and region-specific expression make it an attractive candidate for precision therapies aimed at cognitive enhancement and neuroprotection.
As neuroscience advances toward targeted interventions, GABRA5 stands out as a key molecular player in the development of next-generation treatments for neurodegenerative diseases.
A 1:100 dilution of SMC-494 was sufficient for detection of GABA-A R, Alpha5 in 20 µg of mouse brain lysate by ECL immunoblot analysis using Goat anti-mouse IgG:HRP as the secondary antibody.
Cite this product varies by variant:
- SMC-494D — Size: 100 ug: GABAA Receptor Alpha 5 Antibody (GABRA5) (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-494D, RRID: AB_2702603)
- SMC-494D-A390 — Size: 100 ug: GABAA Receptor Alpha 5 Antibody: ATTO 390 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-494D-A390, RRID: AB_2702604)
- SMC-494D-A488 — Size: 100 ug: GABAA Receptor Alpha 5 Antibody: ATTO 488 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-494D-A488, RRID: AB_2702605)
- SMC-494D-A594 — Size: 100 ug: GABAA Receptor Alpha 5 Antibody: ATTO 594 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-494D-A594, RRID: AB_2702607)
- SMC-494D-APC — Size: 100 ug: GABAA Receptor Alpha 5 Antibody: APC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-494D-APC, RRID: AB_2702613)
- SMC-494D-BI — Size: 100 ug: GABAA Receptor Alpha 5 Antibody: Biotin (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-494D-BI, RRID: AB_2702614)
- SMC-494D-FITC — Size: 100 ug: GABAA Receptor Alpha 5 Antibody: FITC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-494D-FITC, RRID: AB_2702615)
- SMC-494D-HRP — Size: 100 ug: GABAA Receptor Alpha 5 Antibody: HRP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-494D-HRP, RRID: AB_2702616)
- SMC-494D-PCP — Size: 100 ug: GABAA Receptor Alpha 5 Antibody: PerCP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-494D-PCP, RRID: AB_2702618)
- SMC-494D-RPE — Size: 100 ug: GABAA Receptor Alpha 5 Antibody: RPE (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-494D-RPE, RRID: AB_2702619)
- SMC-494S — Size: 12 ug: GABAA Receptor Alpha 5 Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-494S, RRID: AB_2702603)
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
2. Macdonald R.L., Olsen R.W. (1993) Annu Rev Neurosci. 17: 569-602.
3. Hengen K.B., et al. (2012) PLoS One. 7(1): e30608.